# Retractable Technologies Inc: overview RVP · NYSE · CIK 946563 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/rvp.md) · [Financials](/companies/rvp/financials.md) · [Filings](/companies/rvp/filings.md) · [Insiders](/companies/rvp/insiders.md) Latest reported revenue: [$7.2m](/filings/0001104659-26-097216.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001104659-26-097216). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [10.3](/filings/0001104659-25-112205.md) | [9.1 d](/filings/0001104659-26-036053.md) | [8.3](/filings/0001104659-26-062253.md) | [10.4](/filings/0001104659-26-097216.md) | [10.1](/filings/0001104659-25-112205.md) | [9.4 d](/filings/0001104659-26-036053.md) | [7.2](/filings/0001104659-26-062253.md) | [7.2](/filings/0001104659-26-097216.md) | | Gross margin | % | [(0.1%)](/filings/0001104659-25-112205.md) | [(27.5%) d](/filings/0001104659-26-036053.md) | [(0.0%)](/filings/0001104659-26-062253.md) | [(1.0%)](/filings/0001104659-26-097216.md) | [16.7%](/filings/0001104659-25-112205.md) | [(16.2%) d](/filings/0001104659-26-036053.md) | [(11.7%)](/filings/0001104659-26-062253.md) | [2.7%](/filings/0001104659-26-097216.md) | | Operating margin | % | [(49.6%)](/filings/0001104659-25-112205.md) | [(79.6%) d](/filings/0001104659-26-036053.md) | [(56.4%)](/filings/0001104659-26-062253.md) | [(49.1%)](/filings/0001104659-26-097216.md) | [(36.2%)](/filings/0001104659-25-112205.md) | [(81.7%) d](/filings/0001104659-26-036053.md) | [(85.9%)](/filings/0001104659-26-062253.md) | [(71.5%)](/filings/0001104659-26-097216.md) | | Net margin | % | [(18.6%)](/filings/0001104659-25-112205.md) | [41.6% d](/filings/0001104659-26-036053.md) | [(126.6%)](/filings/0001104659-26-062253.md) | [(0.8%)](/filings/0001104659-26-097216.md) | [3.7%](/filings/0001104659-25-112205.md) | [(24.9%) d](/filings/0001104659-26-036053.md) | [(58.9%)](/filings/0001104659-26-062253.md) | [39.3%](/filings/0001104659-26-097216.md) | | Diluted EPS | $ per share | [(0.07)](/filings/0001104659-25-112205.md) | not reported | [(0.35)](/filings/0001104659-26-062253.md) | [0.00](/filings/0001104659-26-097216.md) | [0.01](/filings/0001104659-25-112205.md) | not reported | [(0.14)](/filings/0001104659-26-062253.md) | [0.09](/filings/0001104659-26-097216.md) | | Free cash flow | $m | [(6.5) d](/filings/0001104659-25-112205.md) | [(1.4) d](/filings/0001104659-26-036053.md) | [(1.6)](/filings/0001104659-26-062253.md) | [(4.1) d](/filings/0001104659-26-097216.md) | [(1.3) d](/filings/0001104659-25-112205.md) | not reported | [(1.4)](/filings/0001104659-26-062253.md) | [(1.8) d](/filings/0001104659-26-097216.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [188](/filings/0001558370-24-004361.md) | [94.8](/filings/0001558370-25-003976.md) | [43.6](/filings/0001104659-26-036053.md) | [33.0](/filings/0001104659-26-036053.md) | [38.3](/filings/0001104659-26-036053.md) | | Gross margin | % | [50.6%](/filings/0001558370-24-004361.md) | [29.8%](/filings/0001558370-25-003976.md) | [20.9%](/filings/0001104659-26-036053.md) | [(3.1%)](/filings/0001104659-26-036053.md) | [0.1%](/filings/0001104659-26-036053.md) | | Operating margin | % | [38.5%](/filings/0001558370-24-004361.md) | [(0.9%)](/filings/0001558370-25-003976.md) | [(26.4%)](/filings/0001104659-26-036053.md) | [(63.9%)](/filings/0001104659-26-036053.md) | [(55.3%)](/filings/0001104659-26-036053.md) | | Net margin | % | [29.8%](/filings/0001558370-24-004361.md) | [5.4%](/filings/0001558370-25-003976.md) | [(16.1%)](/filings/0001104659-26-036053.md) | [(36.0%)](/filings/0001104659-26-036053.md) | [(32.8%)](/filings/0001104659-26-036053.md) | | Diluted EPS | $ per share | [1.63](/filings/0001558370-24-004361.md) | [0.15](/filings/0001558370-25-003976.md) | [(0.24)](/filings/0001104659-26-036053.md) | [(0.40)](/filings/0001104659-26-036053.md) | [(0.43)](/filings/0001104659-26-036053.md) | | Free cash flow | $m | [(25.6)](/filings/0001558370-24-004361.md) | [(0.1)](/filings/0001558370-25-003976.md) | [1.9](/filings/0001104659-26-036053.md) | [(13.0)](/filings/0001104659-26-036053.md) | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Gross profit: us-gaap:GrossProfit; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/rvp/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $418.9k | 581,736 | | Unchanged | | [Eversept Partners, LP](/funds/1697013.md) | 2026-06-30 | $418.3k | 580,919 | | Unchanged | | [RENAISSANCE TECHNOLOGIES LLC](/funds/1037389.md) | 2026-06-30 | $317.8k | 441,407 | | Added +37,400 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $173.6k | 241,121 | | Reduced −1 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $87.1k | 121,005 | | Reduced −28,443 | | [BRIDGEWAY CAPITAL MANAGEMENT, LLC](/funds/1107261.md) | 2026-06-30 | $63.8k | 88,543 | | Unchanged | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $62.9k | 87,333 | | New +87,333 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $61.4k | 85,260 | | Unchanged | | [SUSQUEHANNA INTERNATIONAL GROUP, LLP](/funds/1446194.md) | 2026-06-30 | $56.8k | 78,857 | | Added +45,997 | | [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $43.1k | 59,796 | | Unchanged | ## Recent filings [All 906 filings](/companies/rvp/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-30 | 13:36 ET | [8-K](/filings/0001104659-26-112249.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-112249 | | 2026-08-14 | 17:19 ET | [8-K](/filings/0001104659-26-097353.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-097353 | | 2026-08-14 | 16:26 ET | [10-Q](/filings/0001104659-26-097216.md) | Quarterly report, period 2026-06-30 | 0001104659-26-097216 | | 2026-06-30 | 12:28 ET | [8-K](/filings/0001104659-26-079211.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-079211 | | 2026-05-15 | 16:41 ET | [8-K](/filings/0001104659-26-062698.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-062698 | | 2026-05-15 | 13:34 ET | [10-Q](/filings/0001104659-26-062253.md) | Quarterly report, period 2026-03-31 | 0001104659-26-062253 | | 2026-05-13 | 14:15 ET | [8-K](/filings/0001104659-26-060124.md) | 5.07 Shareholder vote results | 0001104659-26-060124 | | 2026-04-10 | 18:03 ET | [8-K](/filings/0001104659-26-041588.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-041588 | | 2026-03-27 | 17:12 ET | [8-K](/filings/0001104659-26-036231.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001104659-26-036231 | | 2026-03-27 | 15:39 ET | [10-K](/filings/0001104659-26-036053.md) | Annual report, period 2025-12-31 | 0001104659-26-036053 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001104659-26-036053.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/d7b5e644-1934-490e-b7fd-90fc8310ad13) ## About the filer - CIK: 946563 - Tickers: RVP - Exchange: NYSE - SIC code: 3841 Surgical & Medical Instruments & Apparatus - State of incorporation: TX - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:29 ET. No prices; not investment advice.